Immunotherapy significantly improved survival rates in patients with head and neck squamous cancer

Head and neck cancer includes tumors such as oral, pharynx, throat, nose and salivary gland tumors, and 90% of all patients with head and neck cancer are squamous cell carcinomas.
Early head and neck squamous cancer can be treated by surgery or radiotherapy to allow some patients to achieve the effect of cure, but 70% to 80% of patients with head and neck cancer are diagnosed at the local late stage or metastatic stage, the need for drug treatment to join.
China Clinical Oncology Society head and neck cancer professional committee chairman, Shanghai Oriental Hospital, deputy director of the Department of Oncology, Professor Guo Wei introduced that China's new diagnosed head and neck cancer patients more than 137,000, and advanced head and neck cancer due to lack of chemotherapy other treatment options, treatment is difficult.
The official website of the National Drug Administration (NMPA) recently revealed that Mercadon PD-1 inhibitor Paboli pearl monodruphargic (Corida) monodramine has been approved for first-line treatment to evaluate metastatic or non-extetable reoccessive head and neck squamous cell carcinoma (HNSCC) patients with PD-L1 expression positive (CPS≥20) through fully validated testing.
This approval is based on the total lifetime data from the keyNOTE-048 study of a large-scale Phase III clinical trial worldwide, which aims to assess the efficacy and safety of patients with relapsed or metastatic head and neck squamous cell carcinoma treated with Paboliju monodrative or combined chemotherapy.
Professor Guo Wei, the KEYNOTE-048 study included a total of 882 patients with relapsed or metastatic head and neck squamous cancer, including oral, oral and pharynx, pharynx and throat cancers, randomly assigned to the Pabloju single anti-monodrative group, the Pabli pearl single anti-combination chemotherapy group and the targeted joint chemotherapy group according to 1:1.1.
the latest data, published in the European EsMO in 2020, according to the KEYNOTE-048 study: Paboliju monoantidehyne-resistant single-drug comparative target combination chemotherapy in patients with PD-L1 positive (CPS≥20), 4 The annual survival rate nearly tripled, from 8% to 21.6%, the efficacy was significantly better than the standard program, the total survival time of patients was extended from 10.8 months to 14.9 months, and the risk of disease death was reduced by 39%, the rate of adverse reactions decreased significantly, and the patient's tolerance was better.
in patients with tumor remission, the medium duration of remission was up to 23.4 months.
Professor Guo Wei said: "At present, squamous cancer is more suitable for immunotherapy and there are many studies on head and neck squamous cancer that have shown a closely related to immune escape, and if immunotherapy can reverse the immune escape of tumors will be a great success in head and neck squamous cancer."
keyNOTE-048 study is a cross-era study of head and neck squamous cancer, which establishes the classic position of Paboli Pearl single-line treatment for recurrence metastatic head and neck squamous cancer.
this year's ESMO long-term data update is even more special.
over time, the long-term survival benefits of Pabliju monoantigen in a certain group of patients have even reached near-cure effects, which is rare in previous treatments.
"()